The Immune Checkpoint Inhibitors Market is segmented by Inhibitor Type (CTLA-4 Inhibitors, PD-1 Inhibitors, Others), Application (Hodgkin Lymphoma, Kidney Cancers, Melanoma, Non-small Cell Lung Cancer, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Region (North America, Europe, Asia-Pacific, and the Rest of the World).

Segment Analysis

Inhibitor Trends

The market has been classified into CTLA-4 inhibitors, PD-1 inhibitors, and others. The PD-1 inhibitors segment accounted for a substantial market share in 2020. This is mainly ascribed to the increased volume of research activities, approvals, and surge in prescriptions of these drugs such as nivolumab and pembrolizumab. In addition, the growing adoption of pembrolizumab, the first PD-1 inhibitor since its approval, owing to its proven efficiency to treat multiple FDA-Approved indications like melanoma, further boosts the segment growth.

Application Trends

The market has been classified into hodgkin lymphoma, kidney cancers, melanoma, non-small cell lung cancer, and others. The dominant application type for immune checkpoint inhibitors (ICIs) is the treatment of cancer. ICIs are a type of immunotherapy that works by targeting proteins on immune cells that regulate immune system activity. By inhibiting these proteins, ICIs can help the immune system recognize and attack cancer cells, leading to improved outcomes for patients with certain types of cancer.

Currently, ICIs are approved for the treatment of several types of cancer, including melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck cancer, bladder cancer, and Hodgkin's lymphoma, among others. The market for ICIs is expected to continue to grow as new indications are approved and as research uncovers new ways to use these drugs to treat cancer and other diseases.

Regional Trends

The market in North America accounted for the largest share in 2020 and is projected to continue its dominance during the review period. This is mainly attributed to the strong presence of well-developed healthcare infrastructure and favorable government initiatives. Moreover, rising innovations in technologically advanced products, immense per capita health expenditures; and increasing prevalence of various chronic diseases such as skin cancer, diabetes, urothelial carcinomas, and lung cancers, which further proliferates the regional growth.

Custom Research: Stratview research offers custom research services across the sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to [email protected].